Table 3.
Enrichment of ENCODE enhancers by genome-wide significant local interactions in the 4p16.1 region in ARIC
| Cell type | All enhancers |
Strongest enhancers |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | Description | Obs. | Exp. | Fold | P-value | Obs. | Exp. | Fold | P-value |
| HepG2 | Hepatocellular carcinoma | 9 | 1.7 | 5.2 | 4.7E−05 | 5 | 0.6 | 8.3 | 3.4E−04 |
| HUVEC | Umbilical vein endothelial cells | 7 | 2.2 | 3.2 | 6.0E−03 | 2 | 1.1 | 1.8 | 3.1E−01 |
| K562 | Leukaemia | 11 | 2.1 | 5.2 | 5.0E−06 | 10 | 0.7 | 15.2 | <1.0E−06 |
| HMEC | Mammary epithelial cells | 7 | 3 | 2.3 | 3.0E−02 | 2 | 1.2 | 1.7 | 3.4E−01 |
| GM12878 | B-lymphocyte lymphoblastoid | 5 | 2.2 | 2.3 | 6.6E−02 | 5 | 0.8 | 6.2 | 1.2E−03 |
| NHEK | Epidermal keratinocytes | 7 | 2.7 | 2.6 | 1.7E−02 | 4 | 1.2 | 3.3 | 3.1E−02 |
Obs.: observed; Exp.: expected; Fold: fold of enrichment calculated as Obs./Exp.; 42 unique epistatic SNPs from Table 1 and Supplementary Material, Table S4 used in the enrichment analysis.